Speciality: Oncology
Description:
Leptomeningeal disease is a challenging complication in cancer patients, often remaining hidden until symptoms appear. Recent advances in cerebrospinal fluid, or CSF, tumor DNA analysis are changing how we screen for this condition. By analyzing tumor DNA fragments in CSF, clinicians can detect occult, or hidden, leptomeningeal disease before it becomes evident on imaging or through neurological symptoms. This approach allows for earlier diagnosis and potentially more effective treatment. Early detection through CSF tumor DNA analysis can help guide therapy decisions and improve patient outcomes. As this technology evolves, it offers new hope for patients at risk of leptomeningeal spread, highlighting the growing role of precision oncology in neuro-oncology care.
See More Webinars @ Hidoc Webinars
1.
Pressing the Sleep button could have a positive impact on cognition.
2.
Experts say oncology, primary care coordination necessary for best cancer patient outcomes
3.
Study sets benchmark for treatment of advanced cervical cancer
4.
As compared to proton therapy, proton therapy is very effective in treating esophageal cancer.
5.
We Don't Always Know What's 'Best' for Our Patients
1.
ERASur: Evaluating Total Ablative Therapy in Limited Metastatic Colorectal Cancer
2.
How Digital Innovation and AI-Powered Case Studies are Revolutionizing Oncology Education?
3.
Predicting Long-Term Endocrine Function After Pancreatic Tumor Resection Through Residual Tissue Adaptation
4.
Unlocking the Mystery of Basilar Artery Stroke: A New Approach to Treatment
5.
Debunking Myths About Systemic Mastocytosis: Separating Fact from Fiction
1.
International Conference on Innovations in Critical Care for Oncology and Cardiology
2.
International Conference on Oncology, Cardiology and Critical Care Policy
3.
International Conference on Oncology, Cancer Prevention and Public Health
4.
International Conference on Cancer Nursing and Rehabilitation Strategies
5.
International Conference on Best Practices in Oncology, Cardiology and Critical Care
1.
Common Cancer Myths Debunked
2.
A Panel Discussion on Clinical Trial End Point for Tumor With PPS > 12 months
3.
Updates on Standard V/S High Risk Myeloma Treatment
4.
Screening for Occult Leptomeningeal Disease Through Cerebrospinal Fluid Tumor DNA Analysis
5.
Navigating the Complexities of Ph Negative ALL - Part X
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation